<!--#if expr="$title" --> <!--#echo var="title" --> <!--#else --> HIV Drug Resistance Database <!--#endif -->
Stanford University HIV Drug Resistance Database - A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance.

MARVEL on integrase mutations at position 148


HIVdb Algorithm: Comments & Scores
  • Q148HKR are nonpolymorphic mutations selected by RAL and EVG (McColl et al. 2007; Cooper et al. 2008; Canducci et al. 2009; Sichtig et al. 2009; Wittkop et al. 2009; Hatano et al. 2010). By itself Q148H reduces RAL and EVG susceptibility about 5-10 fold and Q148RK reduce RAL and EVG susceptibility >30-100 fold. With G140S, Q148HRK reduce RAL and EVG susceptibility >100-fold. (Kobayashi et al. 2008; Fransen et al. 2009b; Jones et al. 2009; Goethals et al. 2010). (McColl et al. 2007; Fransen et al. 2009a; Jones et al. 2009). Q148HKR alone have minimal effects on 9572 susceptibility but cause >10-fold decreased susceptibility in combination with E138K  G140S (Seki et al. 2010).
  • Q148HKR are nonpolymorphic mutations selected by RAL and EVG (McColl et al. 2007; Cooper et al. 2008; Canducci et al. 2009; Sichtig et al. 2009; Wittkop et al. 2009; Hatano et al. 2010). By itself Q148H reduces RAL and EVG susceptibility about 5-10 fold and Q148RK reduce RAL and EVG susceptibility >30-100 fold. With G140S, Q148HRK reduce RAL and EVG susceptibility >100-fold. (Kobayashi et al. 2008; Fransen et al. 2009b; Jones et al. 2009; Goethals et al. 2010). (McColl et al. 2007; Fransen et al. 2009a; Jones et al. 2009). Q148HKR alone have minimal effects on 9572 susceptibility but cause >10-fold decreased susceptibility in combination with E138K  G140S (Seki et al. 2010).
  • Q148HKR are nonpolymorphic mutations selected by RAL and EVG (McColl et al. 2007; Cooper et al. 2008; Canducci et al. 2009; Sichtig et al. 2009; Wittkop et al. 2009; Hatano et al. 2010). By itself Q148H reduces RAL and EVG susceptibility about 5-10 fold and Q148RK reduce RAL and EVG susceptibility >30-100 fold. With G140S, Q148HRK reduce RAL and EVG susceptibility >100-fold. (Kobayashi et al. 2008; Fransen et al. 2009b; Jones et al. 2009; Goethals et al. 2010). (McColl et al. 2007; Fransen et al. 2009a; Jones et al. 2009). Q148HKR alone have minimal effects on 9572 susceptibility but cause >10-fold decreased susceptibility in combination with E138K  G140S (Seki et al. 2010).

MutationRALEVG
Q148H6060
Q148K6060
Q148R6060
Footnote:Mutation scores on the left are derived from published literature linking mutations and ARVs (the complete details can be found in the HIVdb Release Notes).
Genotype-treatment correlation
Mutation frequency according to subtype and drug-class experience.
The frequency of each mutation at position 148 according to subtype and drug-class experience. Data are shown for the 8 most common subtypes. The number of persons in each subtype/treatment category is shown beneath the subtype. Mutations occurring at a frequency >0.5% are shown. Each mutation is also a hyper-link to a separate web page with information on each isolate, including literature references with PubMed abstracts, the GenBank accession number, and complete sequence and treatment records.

PosWTINI Naive Persons INI Treated Persons
A
264
B
2623
C
816
D
124
F
178
G
128
AE
482
AG
371
 
A
1
B
150
C
1
D
6
F
2
G
1
AE
1
AG
2
148 Q      H 0.8     H 17
R 7.7
K 0.7 		      
Footnote: The query page Mutation Prevalence According to Subtype and Treatment to examine the frequency of all mutations according to subtype and treatment; The program HIVSeq provides similar output for mutations in user-submitted sequences; A complete description of the program that generates these tables can be found at Rhee et al AIDS 2006.
 

Genotype-phenotype correlation
Phenotypes of top 10 common patterns of drug resistance mutations with mutations at position 148.
Mutation patterns are listed in the frequency with which they have been reported in the published literature. The median level of fold resistance (compared with wildtype) for viruses with the mutation pattern in the first column are indicated when available. The subscripts indicate the number of viruses that were phenotyped. The drug susceptibility assay used was the PhenoSense assay (Monogram, South San Francisco). A hyperlink for each individual pattern is provided to access a complete list of mutations and fold resistances for each sequence matching the pattern of mutation.

A complete summary of additional in vitro susceptibility data for viruses with Q148 obtained using other assays including the Antivirogram can be found here. A complete list of all mutation patterns with Q148 (not just the top 10 most frequent patterns) can be found at this page.

Mutation PatternsNumber of
Sequences		RAL
foldn		EVG
foldn		DTG
foldn
140S,148H461619100054.11
148R632910951.02
138A,140S,148H6   
92Q,140S,148K,155H5   
138K,147G,148R43421652 
140A,148R412531002 
140S,148R31194 4.01
140S,148H,155H2   
138K,140S,148H2   
92Q,140S,148R,155H2   
Footnote: Mutation patterns were defined by the presence or absence of major INI drug resistance mutations ; Sequences containing a mixture at a major drug resistance positions were excluded; For the cutoffs defined by PhenoSense, open the sample report form provided on this page; The full list of all mutation patterns are also available here.

Database

Resources

Team